Emergent BioSolutions Picks Up a "Warp Speed" Contract to Manufacture Coronavirus Vaccines
Coronavirus vaccine development in the U.S. is about to shift into a higher gear. Emergent BioSolutions (NYSE: EBS), a company that helps the federal government prepare for potential public health threats, received a task order from Uncle Sam valued at around $628 million for the rapid production of leading SARS-CoV-2 vaccine candidates.
Emergent BioSolutions develops and manufactures vaccines that the U.S. government stockpiles in case of an emergency like an outbreak of smallpox or anthrax. Under the aegis of the Warp Speed Program, Washington now wants to put Emergent to work developing and manufacturing some of the vaccine candidates that could prevent further COVID-19 outbreaks.
Image source: Getty Images.
Source Fool.com
